Flustramine Q, a Novel Marine Origin Acetylcholinesterase Inhibitor from Flustra foliacea
Abstract
:1. Introduction
2. Materials and Methods
2.1. Validation of Activity at AChE
2.2. Data Analysis
2.3. Molecular Modelling
3. Results
3.1. In Vitro Activity of Alkaloids from Flustra foliace
3.2. Docking of Flustramine Q into AChE Crystal Structure
3.3. Docking of Flustramine Q In Silico Designed Derivatives into AChE Crystal Structure
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lv, M.; Xu, H. Acetylcholinesterase: A Primary Target for Drugs and Insecticides. Mini-Rev. Med. Chem. 2017, 17, 1665–1676. [Google Scholar] [CrossRef]
- Sharma, K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Mol. Med. Rep. 2019, 20, 1479–1487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greenblatt, H.M.; Dvir, H.; Silman, I.; Sussman, J.L. Acetylcholinesterase. J. Mol. Neurosci. 2003, 20, 369–384. [Google Scholar] [CrossRef] [PubMed]
- Bartus, R.T.; Dean, R.L., 3rd; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408–414. [Google Scholar] [CrossRef]
- Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer’s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66, 137–147. [Google Scholar] [CrossRef] [PubMed]
- Hampel, H.; Mesulam, M.-M.; Cuello, A.C.; Farlow, M.R.; Giacobini, E.; Grossberg, G.T.; Khachaturian, A.S.; Vergallo, A.; Cavedo, E.; Snyder, P.J.; et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 2018, 141, 1917–1933. [Google Scholar] [CrossRef] [PubMed]
- Marucci, G.; Buccioni, M.; Ben, D.D.; Lambertucci, C.; Volpini, R.; Amenta, F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology 2021, 190, 108352. [Google Scholar] [CrossRef]
- Vaz, M.; Silvestre, S. Alzheimer’s disease: Recent treatment strategies. Eur. J. Pharmacol. 2020, 887, 173554. [Google Scholar] [CrossRef]
- Konrath, E.L.; Passos, C.D.S.; Klein-Júnior, L.C.; Henriques, A.T. Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer’s disease. J. Pharm. Pharmacol. 2013, 65, 1701–1725. [Google Scholar] [CrossRef]
- Ng, Y.P.; Or, T.C.T.; Ip, N.Y. Plant alkaloids as drug leads for Alzheimer’s disease. Neurochem. Int. 2015, 89, 260–270. [Google Scholar] [CrossRef]
- Ahmed, F.; Ghalib, R.; Sasikala, P.; Ahmed, K.M. Cholinesterase inhibitors from botanicals. Pharmacogn. Rev. 2013, 7, 121–130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Silva, T.; Reis, J.; Teixeira, J.C.S.; Borges, F. Alzheimer’s disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes. Ageing Res. Rev. 2014, 15, 116–145. [Google Scholar] [CrossRef] [PubMed]
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Tacrine. Available online: https://www.ncbi.nlm.nih.gov/books/NBK547868/ (accessed on 15 January 2020).
- Breijyeh, Z.; Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules 2020, 25, 5789. [Google Scholar] [CrossRef] [PubMed]
- Ago, Y.; Koda, K.; Takuma, K.; Matsuda, T. Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine. J. Pharmacol. Sci. 2011, 116, 6–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Birks, J.S.; Harvey, R.J. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev. 2018, 6, CD001190. [Google Scholar] [CrossRef]
- Kumar, V. Potential medicinal plants for CNS disorders: An overview. Phytother. Res. 2006, 20, 1023–1035. [Google Scholar] [CrossRef]
- Yang, G.; Wang, Y.; Tian, J.; Liu, J.-P. Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. PLoS ONE 2013, 8, e74916. [Google Scholar] [CrossRef] [Green Version]
- Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.G.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2015, 32, 116–211. [Google Scholar] [CrossRef] [Green Version]
- Kiuru, P.; Dʼauria, M.V.; Muller, C.D.; Tammela, P.; Vuorela, H.; Yli-Kauhaluoma, J. Exploring Marine Resources for Bioactive Compounds. Planta Med. 2014, 80, 1234–1246. [Google Scholar] [CrossRef]
- Stonik, V.A. Marine Natural Products: A Way to New Drugs. Acta Nat. 2009, 1, 15–25. [Google Scholar] [CrossRef]
- Moodie, L.W.K.; Sepčić, K.; Turk, T.; Frangež, R.; Svenson, J. Natural cholinesterase inhibitors from marine organisms. Nat. Prod. Rep. 2019, 36, 1053–1092. [Google Scholar] [CrossRef] [PubMed]
- Lima, E.; Medeiros, J. Marine Organisms as Alkaloid Biosynthesizers of Potential Anti-Alzheimer Agents. Mar. Drugs 2022, 20, 75. [Google Scholar] [CrossRef]
- Olsen, E.K.; Hansen, E.; Moodie, L.W.K.; Isaksson, J.; Sepčić, K.; Cergolj, M.; Svenson, J.; Andersen, J.H. Marine AChE inhibitors isolated from Geodia barretti: Natural compounds and their synthetic analogs. Org. Biomol. Chem. 2015, 14, 1629–1640. [Google Scholar] [CrossRef] [PubMed]
- Nukoolkarn, V.S.; Saen-Oon, S.; Rungrotmongkol, T.; Hannongbua, S.; Ingkaninan, K.; Suwanborirux, K. Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp. Bioorganic Med. Chem. 2008, 16, 6560–6567. [Google Scholar] [CrossRef]
- Pan, H.; Qiu, H.; Zhang, K.; Zhang, P.; Liang, W.; Yang, M.; Mou, C.; Lin, M.; He, M.; Xiao, X.; et al. Fascaplysin Derivatives Are Potent Multitarget Agents against Alzheimer’s Disease: In Vitro and in Vivo Evidence. ACS Chem. Neurosci. 2019, 10, 4741–4756. [Google Scholar] [CrossRef]
- Mishchenko, N.; Fedoreev, S.A.; Bagirova, V.L. Histochrome: A New Original Domestic Drug. Pharm. Chem. J. 2003, 37, 48–52. [Google Scholar] [CrossRef]
- Di, X.; Wang, S.; Oskarsson, J.T.; Rouger, C.; Tasdemir, D.; Hardardottir, I.; Freysdottir, J.; Wang, X.; Molinski, T.F.; Omarsdottir, S. Bromotryptamine and Imidazole Alkaloids with Anti-inflammatory Activity from the Bryozoan Flustra foliacea. J. Nat. Prod. 2020, 83, 2854–2866. [Google Scholar] [CrossRef] [PubMed]
- Ellman, G.L.; Courtney, K.D.; Andres, V., Jr.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–90. [Google Scholar] [CrossRef]
- Cheung, J.; Rudolph, M.J.; Burshteyn, F.; Cassidy, M.S.; Gary, E.N.; Love, J.; Franklin, M.C.; Height, J.J. Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands. J. Med. Chem. 2012, 55, 10282–10286. [Google Scholar] [CrossRef] [PubMed]
- Sastry, G.M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 2013, 27, 221–234. [Google Scholar] [CrossRef]
- Jorgensen, W.L.; Maxwell, D.S.; Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J. Am. Chem. Soc. 1996, 118, 11225–11236. [Google Scholar] [CrossRef]
- Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem. 2004, 47, 1739–1749. [Google Scholar] [CrossRef] [PubMed]
- Yu, Q.-S.; Greig, N.H.; Holloway, H.W.; Brossi, A. Syntheses and Anticholinesterase Activities of (3aS)-N,N8-Bisnorphenserine, (3aS)-N1,N8-Bisnorphysostigmine, Their Antipodal Isomers, and Other Potential Metabolites of Phenserine. J. Med. Chem. 1998, 41, 2371–2379. [Google Scholar] [CrossRef]
- Koellner, G.; Kryger, G.; Millard, C.B.; Silman, I.; Sussman, J.; Steiner, T. Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica. J. Mol. Biol. 2000, 296, 713–735. [Google Scholar] [CrossRef] [Green Version]
- Kishimoto, S.; Hara, K.; Hashimoto, H.; Hirayama, Y.; Champagne, P.A.; Houk, K.N.; Tang, Y.; Watanabe, K. Enzymatic one-step ring contraction for quinolone biosynthesis. Nat. Commun. 2018, 9, 2826. [Google Scholar] [CrossRef] [Green Version]
- Feldman, K.S.; Coca, A. Synthesis of the pentacyclic core of lihouidine. Tetrahedron Lett. 2008, 49, 2136–2138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M.V.; et al. Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds. J. Med. Chem. 2009, 52, 5365–5379. [Google Scholar] [CrossRef] [PubMed]
- Zhao, T.; Ding, K.-M.; Zhang, L.; Cheng, X.-M.; Wang, C.-H.; Wang, Z.-T. Acetylcholinesterase and Butyrylcholinesterase Inhibitory Activities of β-Carboline and Quinoline Alkaloids Derivatives from the Plants of Genus Peganum. J. Chem. 2013, 2013, 717232. [Google Scholar] [CrossRef] [Green Version]
- Isomae, K.; Ishikawa, M.; Ohta, M.; Ogawa, Y.; Hasegawa, H.; Kohda, T.; Kamei, J. Effects of T-82, a New Quinoline Derivative, on Cholinesterase Activity and Extracellular Acetylcholine Concentration in Rat Brain. Jpn. J. Pharmacol. 2002, 88, 206–212. [Google Scholar] [CrossRef] [Green Version]
- Fu, J.; Bao, F.; Gu, M.; Liu, J.; Zhang, Z.; Ding, J.; Xie, S.-S.; Ding, J. Design, synthesis and evaluation of quinolinone derivatives containing dithiocarbamate moiety as multifunctional AChE inhibitors for the treatment of Alzheimer’s disease. J. Enzym. Inhib. Med. Chem. 2019, 35, 118–128. [Google Scholar] [CrossRef]
- Cummings, J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin. Transl. Sci. 2017, 11, 147–152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loera-Valencia, R.; Cedazo-Minguez, A.; Kenigsberg, P.; Page, G.; Duarte, A.; Giusti, P.; Zusso, M.; Robert, P.; Frisoni, G.B.; Cattaneo, A.; et al. Current and Emerging Avenues for Alzheimer’s Disease Drug Targets. J. Intern. Med. 2019, 286, 398–437. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Knight, R.; Khondoker, M.; Magill, N.; Stewart, R.; Landau, S. A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia. Dement. Geriatr. Cogn. Disord. 2018, 45, 131–151. [Google Scholar] [CrossRef] [PubMed]
Compound Name | AChE %Inhibition IC50 (µM) pIC50 ± SEM | Compound Name | AChE %Inhibition IC50 (µM) pIC50 ± SEM |
---|---|---|---|
Physostigmine * | IC50 = 0.78 (6.13 ± 0.02) | 12 | 17.8 ± 4% |
1 Flustramine Q | 82.1 ± 1% IC50 = 9.6 ± 4 | 13 | 43.3 ± 2% |
21 Flustramine I | 47.9 ± 6% IC50 = 113 ± 8 | 14 | 32.7 ± 3% |
2 Flustramine R | 28.4 ± 1% | 15 Deformylflustrabromine | 44.2 ± 4% |
3 Flustramine T | 31.5 ± 4% | 16 Flustramine L | 9.7 ± 3.4% |
4 Flustramine V | 26.9 ± 2% | 17 Dihydroflustramine C | 31.7 ± 3% |
5 Flustramine W | 24.4 ± 1% | 18 Flustramine A | 21.7 ± 6.8% |
6 Flustraminol C | 23.2 ± 2% | 19 Flustramine E | 47.8 ± 2% |
7 Flustraminol D | 17.2 ± 2% | 20 Flustramine B | 43.0 ± 3.2% |
8 Flustraminol E | 31.3 ± 12% | 22 Flustramine C | 19.2 ± 4.7% |
9 Flustraminol F | 9.1 ± 2% | 23 | 11.7 ± 1.5% |
10 Flustraminol G | 17.7 ± 4% | 24 Flustrimidazole A | 25.2 ± 3% |
11 Flustraminol H | 23.5 ± 2% | 25 Flustrimidazole B | 3.8 ± 1% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kowal, N.M.; Di, X.; Omarsdottir, S.; Olafsdottir, E.S. Flustramine Q, a Novel Marine Origin Acetylcholinesterase Inhibitor from Flustra foliacea. Future Pharmacol. 2023, 3, 38-47. https://doi.org/10.3390/futurepharmacol3010003
Kowal NM, Di X, Omarsdottir S, Olafsdottir ES. Flustramine Q, a Novel Marine Origin Acetylcholinesterase Inhibitor from Flustra foliacea. Future Pharmacology. 2023; 3(1):38-47. https://doi.org/10.3390/futurepharmacol3010003
Chicago/Turabian StyleKowal, Natalia M., Xiaxia Di, Sesselja Omarsdottir, and Elin S. Olafsdottir. 2023. "Flustramine Q, a Novel Marine Origin Acetylcholinesterase Inhibitor from Flustra foliacea" Future Pharmacology 3, no. 1: 38-47. https://doi.org/10.3390/futurepharmacol3010003